Drug intelligence / Profile preview

AP-003

Development stage: Unknown
Lead developer: BetterLife Pharma
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Inhalation

Overview

AP-003 is an inhaled recombinant human interferon alpha-2b therapy developed by Altum Pharmaceuticals, which was acquired by BetterLife Pharma. It is primarily being investigated as a potential antiviral treatment for early-stage COVID-19. The drug works by leveraging the immunomodulatory and antiviral properties of interferon alpha-2b. Following its acquisition, BetterLife Pharma pivoted its focus to advance AP-003 through clinical development for viral infections and potentially cancer.

Other names: interferon alpha-2binhaled interferon alpha-2brhIFN-alpha2brhIFN-alpha-2brhIFN-alpha 2binterferon-alpha2b-Pontificia Universidad Catolica de Chile-COVID-19interferon-alpha-2b-Pontificia Universidad Catolica de Chile-COVID-19interferon-alpha 2b-Pontificia Universidad Catolica de Chile-COVID-19

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on AP-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-003.

Explore the full profile